View Item 

Show simple item record

Effectiveness of 8‐ or 12‐weeks of ledipasvir and sofosbuvir in real‐world treatment‐naïve, genotype 1 hepatitis C infected patients
dc.contributor.authorCurry, M. P.
dc.contributor.authorTapper, E. B.
dc.contributor.authorBacon, B.
dc.contributor.authorDieterich, D.
dc.contributor.authorFlamm, S. L.
dc.contributor.authorGuest, L.
dc.contributor.authorKowdley, K. V.
dc.contributor.authorLee, Y.
dc.contributor.authorMilligan, S.
dc.contributor.authorTsai, N.
dc.contributor.authorYounossi, Z.
dc.contributor.authorAfdhal, N. H.
dc.date.accessioned2017-10-05T18:18:19Z
dc.date.available2018-12-03T15:34:03Zen
dc.date.issued2017-09
dc.identifier.citationCurry, M. P.; Tapper, E. B.; Bacon, B.; Dieterich, D.; Flamm, S. L.; Guest, L.; Kowdley, K. V.; Lee, Y.; Milligan, S.; Tsai, N.; Younossi, Z.; Afdhal, N. H. (2017). "Effectiveness of 8‐ or 12‐weeks of ledipasvir and sofosbuvir in real‐world treatment‐naïve, genotype 1 hepatitis C infected patients." Alimentary Pharmacology & Therapeutics (5): 540-548.
dc.identifier.issn0269-2813
dc.identifier.issn1365-2036
dc.identifier.urihttps://hdl.handle.net/2027.42/138307
dc.publisherWiley Periodicals, Inc.
dc.titleEffectiveness of 8‐ or 12‐weeks of ledipasvir and sofosbuvir in real‐world treatment‐naïve, genotype 1 hepatitis C infected patients
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOtolaryngology
dc.subject.hlbsecondlevelPharmacy and Pharmacology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/138307/1/apt14204.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/138307/2/apt14204_am.pdf
dc.identifier.doi10.1111/apt.14204
dc.identifier.sourceAlimentary Pharmacology & Therapeutics
dc.identifier.citedreferencePillai AA, Maheshwari R, Vora R, et al. Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin. Aliment Pharmacol Ther. 2017; 45: 1427 ‐ 1432.
dc.identifier.citedreferenceEuropean Association for Study of Liver. EASL recommendation on treatment of heaptitis C 2015. J Hepatol. 2015; 63: 199 ‐ 236.
dc.identifier.citedreferenceUK National Institute for Health Care and Excellence. Appraisal consultation document. Ledipasvir‐sofosbuvir for treating chronic hepatitis C, 2015. https://www.nice.org.uk/guidance/ta363. Accessed January 2017.
dc.identifier.citedreferenceMarshall VJ, Rife K, Hirsch A, et al. Real life treatmet outcomes with 8 week course treatment for hepatitis C without cirrhosis confirmed by transient elastography. Hepatology. 2015; 62 ( Suppl 1 ): 779A.
dc.identifier.citedreferenceRoytman M, Tang AL, Wu C, et al. Real Life Experience with Sofosbuvir and Ledipasvir fixed does regemine in the multicentric cohort of patients with chronic hepatitis C. Hepatology. 2015; 62 ( Suppl 1 ): 761A.
dc.identifier.citedreferenceBuggisch B, Boker K, Gunther R, et al. Ledipasvire/Sofosbuvir (LDV/SOF) for 8 weeks in genotype 1 (GT1) treastment‐naive non cirrhotic patients with HCV viraload < 6 millionsIU/ML (6M): a comparative analysis of the phase‐3 ION‐3 data and real world effectiveness. J Hepatol. 2016; 64: S810.
dc.identifier.citedreferenceCrespo J, Fernandez I, Cabezas J, et al. Effectiveness and safety of sofosbuvir / Ledipasvir treatment for monoinfected genotype 1 HCV patients in rela life clinical practice: results fo the Spanish Hepa‐C cohort. J Hepatol. 2016; 64: S217.
dc.identifier.citedreferenceLai JB, Witt MA, Witt DJ. Real World Effectiveness of 8, 12 and 24 weeks of Ledipasvire(LDV)/Sofosbuvir(SOF)‐ based therapy for heaptitis C (HCV) genotype 1: analysis in a large integrated health care system. J Hepatol. 2016; 64: S778.
dc.identifier.citedreferenceLatt NL, Gevorkyan R, Yanny BT, Sahota A. Ledipasvir / Sofosbuvir for 8 weeks in non cirrhotic treatment naive patients with genotype 1 hepatitis C infection: real life experience in a community setting. J Hepatol. 2016; 64: S802.
dc.identifier.citedreferenceQureshi K, Andres J, Regester J, et al. Real‐Life outcomes of 8 weeks regimen of sofosbuvir and ledipasvir without ribavirin in non cirrhotics treatment naive hepatitis C genotype 1 patients with less thatn 6 millions IU/ML viral load. J Hepatol. 2016; 64: S786.
dc.identifier.citedreferenceTerrault NA, Zeuzem S, Di Bisceglie AM, et al. Effectiveness of ledipasvir‐sofosbuvir combination in patients with hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. Gastroenterology. 2016; 151: 1131 ‐ 1140 e5.
dc.identifier.citedreferenceO’Brien TR, Feld JJ, Kottilil S, Pfeiffer RM. No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA <6,000,000 IU/mL. Hepatology. 2016; 63: 28 ‐ 30.
dc.identifier.citedreferenceMoon AM, Green PK, Berry K, Iannou GN. Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents. Aliment Pharmacol Ther. 2017; 45: 1201 ‐ 1212.
dc.identifier.citedreferenceGuarino M, Morisco F, Valvano MR, et al. Systematic review: interferon‐free regimens for patients with HCV‐related Child C cirrhosis. Aliment Pharmacol Ther. 2017; 45: 1193 ‐ 1200.
dc.identifier.citedreferenceReddy KR, Kim JK, Kuo A, et al. All‐oral direct‐acting antiviral therapy in HCV‐advanced liver disease is effective in real‐world practice: observations through HCV‐TARGET database. Aliment Pharmacol Ther. 2017; 45: 115 ‐ 126.
dc.identifier.citedreferenceDieterich D, Bacon BR, Curry MP, et al. Access to therapy in the era of all DAA regimens: real world experiences from the TRIO Network. Gastroenterology. 2016; 150: S1040.
dc.identifier.citedreferenceYounossi ZM, Bacon BR, Dieterich DT, et al. Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network. J Viral Hepat. 2016; 23: 447 ‐ 454.
dc.identifier.citedreferenceIoannou GN, Beste LA, Chang MF, et al. Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System. Gastroenterology. 2016; 151: 457 ‐ 471.
dc.identifier.citedreferenceTapper EB, Bacon BR, Curry MP, et al. Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real‐world cohort study. Hepatology. 2016; 64: 1893 ‐ 1899.
dc.identifier.citedreferenceWilder JM, Jeffers LJ, Ravendhran N, et al. Safety and efficacy of ledipasvir‐sofosbuvir in black patients with hepatitis C virus infection: a retrospective analysis of phase 3 data. Hepatology. 2016; 63: 437 ‐ 444.
dc.identifier.citedreferenceBackus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Real‐world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment‐naive, genotype 1 hepatitis C‐infected patients. Hepatology. 2016; 64: 405 ‐ 414.
dc.identifier.citedreferenceChronic hepatitis C virus (HCV) infection: treatment considerationsfrom the Department of Veternas Affairs National Hepatitis C Resource Center Program and national Viral Hepatitis Program. http://www.hepatitis.va.gov/provider/index.asp Accessed March 2017.
dc.identifier.citedreferenceTerrault NA, Zeuzem S, Di Bisceglie AM, et al. Treatment Outcomes with 8, 12 and 24 week regimens of Ledipasvir/Sofosbuvir for the treatment of heaptitis C infection: analysis of a multicenter prospective, onservational study. Hepatology. 2015; 62 ( Suppl 1 ): 256A.
dc.identifier.citedreferenceLai JB, Witt MA, Pauly MP, et al. Eight‐ or 12‐week treatment of hepatitis C with ledipasvir/sofosbuvir: real‐world experience in a large integrated health system. Drugs. 2017; 77: 313 ‐ 318.
dc.identifier.citedreferenceIngiliz P, Christensen S, Kimhofer T, et al. Sofosbuvir and ledipasvir for 8 weeks for the treatment of chronic hepatitis C virus (HCV) infection in HCV‐monoinfected and HIV‐HCV‐coinfected individuals: results from the German hepatitis C cohort (GECCO‐01). Clin Infect Dis. 2016; 63: 1320 ‐ 1324.
dc.identifier.citedreferenceMohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age‐specific antibody to HCV seroprevalence. Hepatology. 2013; 57: 1333 ‐ 1342.
dc.identifier.citedreferenceGower E, Estes C, Blach S, Razavi‐Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014; 61 ( Suppl 1 ): S45 ‐ S57.
dc.identifier.citedreferenceRazavi H, Waked I, Sarrazin C, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm. J Viral Hepat. 2014; 21 ( Suppl 1 ): 34 ‐ 59.
dc.identifier.citedreferencevan der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all‐cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012; 308: 2584 ‐ 2593.
dc.identifier.citedreferenceYounossi ZM, Stepanova M, Sulkowski M, Naggie S, Henry L, Hunt S. Sofosbuvir and ledipasvir improve patient‐reported outcomes in patients co‐infected with hepatitis C and human immunodeficiency virus. J Viral Hepat. 2016; 23: 857 ‐ 865.
dc.identifier.citedreferenceIyengar S, Tay‐Teo K, Vogler S, et al. Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis. PLoS Med. 2016; 13: e1002032.
dc.identifier.citedreferenceChhatwal J, He T, Lopez‐Olivo MA. Systematic review of modelling approaches for the cost effectiveness of hepatitis C treatment with direct‐acting antivirals. Pharmacoeconomics. 2016; 34: 551 ‐ 567.
dc.identifier.citedreferenceChhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost‐effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med. 2015; 162: 397 ‐ 406.
dc.identifier.citedreferenceYounossi ZM, Park H, Saab S, Ahmed A, Dieterich D, Gordon SC. Cost‐effectiveness of all‐oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther. 2015; 41: 544 ‐ 563.
dc.identifier.citedreferenceKowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014; 370: 1879 ‐ 1888.
dc.identifier.citedreferenceAfdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014; 370: 1889 ‐ 1898.
dc.identifier.citedreferenceUS Food Drug Administration. Centre for drug evaluation and research. Sofosbuvir and ledipasvir fixed‐dose combination, in 2014: NDA 205834. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205834Orig1s000MedR.pdf. Accessed January 2017.
dc.identifier.citedreferenceAASLD‐IDSA. Initial treatment fo HCV infection. http://www.hcvguidelines.org/full-report/initial-treatment-hcv-infection Accessed July 2016.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
apt14204.pdf
Size:
669.1KB
Format:
PDF
View/Open
Name:
apt14204_am.pdf
Size:
476.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.